$LGVN SEC Filings

Filed On	Filing
26 Oct 2026	8-K: Other Events Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
14 Oct 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers (b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026.
05 Oct 2026	Form 4: Jhaveri Nirav S., Chief Financial Officer Gave up 742 shares to cover exercise price or tax ($1.92K)
05 Oct 2026	Form 4: Willard Stephen H, Chief Executive Officer Gave up 1,987 shares to cover exercise price or tax ($5.15K)
05 Oct 2026	Form 4: Agafonova Nataliya, Chief Medical Officer Gave up 2,913 shares to cover exercise price or tax ($7.54K)
05 Oct 2026	Form 4: Lehr Paul T, General Counsel, Secretary Gave up 2,253 shares to cover exercise price or tax ($5.84K)
05 Oct 2026	Form 4: Blass Devin, CTO & SVP of CMC Gave up 2,520 shares to cover exercise price or tax ($6.53K)
23 Sep 2026	8-K: Other Events Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
14 Sep 2026	8-K: Other Events As previously disclosed, on September 22, 2025, Longeveron Inc. (the “Company”) received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) advising that the Company was not in compliance with the $1.00 ...
10 Sep 2026	SCHEDULE 13G
25 Aug 2026	Form 4: Jhaveri Nirav S., Chief Financial Officer Received 300,000 shares as a grant or award
25 Aug 2026	Form 3: Jhaveri Nirav S., Chief Financial Officer Holds 0 shares of Class A Common Stock
24 Aug 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure
21 Aug 2026	Form 4: Lehr Paul T, General Counsel, Secretary Received 286,000 shares as a grant or award
21 Aug 2026	Form 4: Hajjar Roger Joseph, Director Received 36,000 shares as a grant or award
21 Aug 2026	Form 4: Soffer Rock, Director Received 36,000 shares as a grant or award
21 Aug 2026	Form 4: Paletta George A. Jr., Director Received 36,000 shares as a grant or award
21 Aug 2026	Form 4: Ungaro Ursula, Director Received 36,000 shares as a grant or award
21 Aug 2026	Form 4: Cann Leah Rush, Director Received 36,000 shares as a grant or award
21 Aug 2026	Form 4: Desai Arjun Jj, Director Received 36,000 shares as a grant or award

Comments